

## Terumo Appoints the Candidates for Directors

TOKYO, JAPAN – May 12, 2021 – Terumo Corporation (TSE: 4543) hereby announces that it has decided the candidates for directors as below. The elections are subject to the approval of the Annual General Meeting of Shareholders to be held on June 22, 2021.

### 1. Candidates for directors

#### (Excluding directors who serve as Audit/Supervisory Committee Members)

Name	New position	Current position
Takayoshi Mimura	Chairman of the Board	Same as on the left
Shinjiro Sato	President and CEO	Same as on the left
Toshiaki Takagi	Director and Senior Managing Executive Officer	Same as on the left
Shoji Hatano	Director and Managing Executive Officer	Same as on the left
Kyo Nishikawa	Director and Managing Executive Officer	Same as on the left
Yukiko Kuroda	Independent Director	Same as on the left
Hidenori Nishi	Independent Director	Same as on the left
Keiya Ozawa	Independent Director	(New candidate)

### 2. Candidates for directors who serve as Audit/Supervisory Committee Members

Name	New position	Current position
Takanori Shibazaki	Director who serves as an Audit/Supervisory Committee Member	Senior Executive Officer
Masaichi Nakamura	Independent director who serves as an Audit/Supervisory Committee Member	Same as on the left
Soichiro Uno	Independent director who serves as an Audit/Supervisory Committee Member	Same as on the left

### 3. New Candidate for directors

Keiya Ozawa (Professor Emeritus, Visiting Professor of Jichi Medical University: JMU)

Name	Professional Career	
Keiya Ozawa (Born on February 23, 1953)	March 1977	Graduated from the Faculty of Medicine, The University of Tokyo
	March 1985	National Institutes of Health, U.S.A. (Fogarty Fellow -1987)
	September 1990	Associate Professor, The Institute of Medical Science, The University of Tokyo
	November 1994	Professor, Institute of Hematology, JMU
	February 1998	Professor and Chairman, Division of Hematology, JMU
	April 1998	Professor, Division of Genetic Therapeutics, Center for Molecular Medicine, JMU
	December 2012	Chairperson, Hematopoietic Stem Cell Transplantation Subcommittee, Specific Diseases Control Committee, Ministry of Health, Labour and Welfare (present)
	April 2014	Director, IMSUT (The Institute of Medical Science, The University of Tokyo) Hospital; Director, Center for Gene & Cell Therapy (CGCT); Professor, Division of Genetic Therapeutics, The Advanced Clinical Research Center, IMSUT Visiting Professor, Division of Immuno- Gene & Cell Therapy, JMU (present)
	April 2018	Professor Emeritus and Visiting Professor, JMU (present) Senior Adviser, Center for Gene Therapy Research (CGTR), JMU (present) Program Supervisor, Japan Agency for Medical Research and Development (AMED) (present)
June 2018	Program Officer, AMED (present)	

Takanori Shibazaki (Senior Executive Officer)

Name	Professional Career	
Takanori Shibazaki (Born on December 25, 1961)	April 1986	Joined the Company
	July 2005	Factory Manager of Terumo Medical Products (Hangzhou) Co., Ltd. 1 <sup>st</sup> Factory
	September 2007	Deputy General Manager of Strategic Planning Dept.
	October 2008	President and CEO, Terumo Medical Products (Hangzhou) Co., Ltd.
	April 2014	Executive Officer
	July 2014	General Manager, Supply Chain Management Dept.
	April 2016	President and CEO, Terumo (China) Holding Co., Ltd.
	April 2017	Senior Executive Officer, Regional Representative, China (present)

#### **4. Director to resign from the Board**

Ryuzo Ueda

Yoshihiro Kimura

#### **About Terumo**

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.

###